Last reviewed · How we verify
omeprazole, caffeine, flurbiprofen, rosiglitazone
At a glance
| Generic name | omeprazole, caffeine, flurbiprofen, rosiglitazone |
|---|---|
| Also known as | omeprazole, caffeine, flurbiprofen, rosiglitazone, GSK626616 |
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Validation Study of Multiple Probe Compounds for Drug Interaction Evaluation (PHASE1)
- A Placebo-controlled Study to Investigate the Safety, and Pharmacokinetics of Oral GSK626616AC in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: